All In Biotech

Drug Trial Radar · NCT01493414

INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis.

An Open-label, Multicenter, Expanded Access Study of INC424 for Patients With Primary Myelofibrosis (PMF) or Post Polycythemia Myelofibrosis (PPV MF) or Post-essential Thrombocythemia Myelofibrosis (PET-MF).

Last checked: Nov 19, 2026Latest source record: Apr 26, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,233

Actual

Start

Aug 16, 2011

Primary completion

Jan 26, 2017

Study completion Jan 26, 2017

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Dec 16, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study was to collect additional safety of INC424 in patients with Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis, who either received prior treatment with commercially available agents or who have never received treatment.

Conditions

  • Myelofibrosis

Interventions

  • INC424Drug

    All patients enrolled into the study will receive INC424 (ruxolitinib). Starting dose is based on baseline platelet counts, with doses ranging from 5 to 20 mg twice a day. No INC424 dose will exceed 25 mg BID orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 5 YearsTime frame: Baseline up to approximately 5 years

Locations

273 sites in 25 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Algiers, Algeria

  • Novartis Investigative Site

    Buenos Aires, Argentina

  • Novartis Investigative Site

    Córdoba, Argentina

  • Novartis Investigative Site

    Corrientes, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    Paraná, Entre Ríos Province, Argentina

  • Novartis Investigative Site

    Graz, Austria

  • Novartis Investigative Site

    Linz, Austria

  • Novartis Investigative Site

    Linz, Austria

  • Novartis Investigative Site

    Salzburg, Austria

  • Novartis Investigative Site

    Vienna, Austria

  • Novartis Investigative Site

    Vienna, Austria

  • Novartis Investigative Site

    Innsbruck, Tyrol, Austria

  • Novartis Investigative Site

    Antwerp, Belgium

  • Novartis Investigative Site

    Bruges, Belgium

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Charleroi, Belgium

  • Novartis Investigative Site

    Edegem, Belgium

  • Novartis Investigative Site

    Ghent, Belgium

  • Novartis Investigative Site

    Hasselt, Belgium

  • Novartis Investigative Site

    Kortrijk, Belgium

  • Novartis Investigative Site

    Leuven, Belgium

  • Novartis Investigative Site

    Liège, Belgium

  • Novartis Investigative Site

    Roeselare, Belgium

  • Novartis Investigative Site

    Wilrijk, Belgium

  • Novartis Investigative Site

    Yvoir, Belgium

  • Novartis Investigative Site

    Arlon, Luxembourg, Belgium

  • Novartis Investigative Site

    Goiânia, Goiás, Brazil

  • Novartis Investigative Site

    Belo Horizonte, Minas Gerais, Brazil

  • Novartis Investigative Site

    Curitiba, Paraná, Brazil

  • Novartis Investigative Site

    Rio de Janeiro, Rio de Janeiro, Brazil

  • Novartis Investigative Site

    Porto Alegre, Rio Grande do Sul, Brazil

  • Novartis Investigative Site

    Campinas, São Paulo, Brazil

  • Novartis Investigative Site

    Ribeirão Preto, São Paulo, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil

  • Novartis Investigative Site

    Edmonton, Alberta, Canada

Showing 40 of 273 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.